GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
F

Fusen Pharmaceutical Co 1652.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

0.95

—

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥273.4m

FY2016FY2025

Net income

−CN¥11.8m

FY2016FY2025

Free cash flow

CN¥70.0m

FY2016FY2025

Shareholders' equity

CN¥359.4m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥273.4mCN¥278.9mCN¥483.8mCN¥420.6mCN¥329.9mCN¥486.9mCN¥407.4mCN¥462.1mCN¥452.6mCN¥442.0m
Gross profitCN¥109.8mCN¥139.1mCN¥256.2mCN¥192.5mCN¥180.6mCN¥266.1mCN¥212.5mCN¥251.3mCN¥251.9mCN¥222.2m
Research and developmentCN¥13.3mCN¥90.9mCN¥69.3mCN¥13.2mCN¥9.1mCN¥27.3mCN¥11.6mCN¥11.2mCN¥3.4mCN¥701,000
Operating income−CN¥25.9m−CN¥57.7mCN¥17.1mCN¥13.5mCN¥44.6mCN¥87.8mCN¥66.1mCN¥136.1mCN¥122.2mCN¥118.6m
Net income−CN¥11.8m−CN¥161.5m−CN¥31.0m−CN¥29.6mCN¥14.2mCN¥70.1mCN¥53.4mCN¥101.9mCN¥96.8mCN¥95.1m
Diluted earnings per share-0.02-0.22-0.04-0.040.020.090.070.130.120.16

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥1.26bnCN¥1.06bnCN¥1.15bnCN¥1.16bnCN¥1.06bnCN¥1.24bnCN¥1.18bnCN¥1.16bnCN¥951.2mCN¥1.15bn
Cash and short-term investmentsCN¥83.9mCN¥18.0mCN¥29.8mCN¥109.6mCN¥69.9mCN¥312.5mCN¥331.0mCN¥561.1mCN¥474.6mCN¥244.4m
Total liabilitiesCN¥891.0mCN¥744.0mCN¥668.5mCN¥630.7mCN¥498.2mCN¥583.1mCN¥494.7mCN¥547.2mCN¥768.4mCN¥1.02bn
DebtCN¥324.3mCN¥328.2mCN¥294.4mCN¥195.4mCN¥205.9mCN¥198.5mCN¥210.0mCN¥190.0mCN¥391.6mCN¥600.7m
Shareholders' equityCN¥359.4mCN¥316.2mCN¥482.0mCN¥525.4mCN¥563.0mCN¥659.4mCN¥673.4mCN¥613.9mCN¥180.6mCN¥121.1m
Shares outstanding739m739m749m753m769m779m806m790m800m600m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥121.9mCN¥114.4m−CN¥62.7mCN¥94.5mCN¥40.9mCN¥153.2mCN¥20.4mCN¥62.8mCN¥133.2mCN¥172.3m
Capital spending−CN¥52.0m−CN¥65.3m−CN¥75.7m−CN¥20.4m−CN¥94.2m−CN¥58.6m−CN¥200.3m−CN¥104.4m−CN¥9.1m−CN¥20.0m
Free cash flowCN¥70.0mCN¥49.1m−CN¥138.4mCN¥74.1m−CN¥53.3mCN¥94.6m−CN¥179.9m−CN¥41.5mCN¥124.1mCN¥152.4m
Dividends paid———−CN¥6.0m−CN¥7.1m−CN¥3.1m−CN¥5.3m−CN¥1.1m−CN¥25.0m−CN¥157.3m

Latest quarters

By quarter end

Jun 2026Dec 2025Jun 2025Dec 2024Sept 2024Jun 2024Mar 2024Dec 2023
RevenueCN¥114.2mCN¥162.1mCN¥111.3mCN¥111.0mCN¥64.9mCN¥167.9mCN¥98.2mCN¥196.0m
Gross profitCN¥49.2mCN¥66.8mCN¥43.0mCN¥48.6mCN¥28.4mCN¥90.6mCN¥52.9mCN¥103.0m
Operating incomeCN¥4.5mCN¥18.5m−CN¥20.2m−CN¥26.5m−CN¥15.5m−CN¥31.3m−CN¥18.3m−CN¥15.5m
Net income−CN¥13.7mCN¥11.4m−CN¥23.1m−CN¥129.9m−CN¥75.9m−CN¥31.6m−CN¥18.5m−CN¥45.1m
Diluted earnings per share-0.020.02-0.03-0.18-0.10-0.04-0.02-0.06
Cash from operations—CN¥92.0mCN¥31.0mCN¥119.0m—−CN¥5.0m−CN¥3.0m−CN¥23.0m
Capital spending—−CN¥45.0m−CN¥3.0m−CN¥25.0m—−CN¥39.0m−CN¥22.0m−CN¥20.0m
Free cash flow—CN¥47.0mCN¥28.0mCN¥94.0m—−CN¥44.0m−CN¥25.0m−CN¥43.0m
Total assetsCN¥1.24bnCN¥1.26bnCN¥1.23bnCN¥1.06bnCN¥1.24bnCN¥1.14bnCN¥1.34bnCN¥1.34bn
Cash and short-term investmentsCN¥87.8mCN¥83.9mCN¥76.0mCN¥18.0mCN¥21.1mCN¥2.4mCN¥2.8mCN¥34.8m
DebtCN¥307.4mCN¥301.2mCN¥364.7mCN¥328.2mCN¥304.5mCN¥299.9mCN¥242.3mCN¥347.9m
Shareholders' equityCN¥345.5mCN¥359.4mCN¥346.6mCN¥316.2mCN¥369.7mCN¥445.2mCN¥520.5mCN¥563.5m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-13.4%-10.9%-2.9%
Net income-26.5%——

Average margins

Over each period

1 year3 years5 years10 years
Gross margin45.1%47.9%50.3%51.2%
Operating margin-15.1%-3.6%3.5%13.8%
Net margin-31.4%-16.1%-6.6%5.5%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Price to earnings-43.4-3.2-28.6-31.458.043.462.716.5
Price to sales1.91.81.82.22.56.38.23.6

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years. Last went ex-dividend on 7 Jun 2022.

FY2022FY2021FY2020FY2019FY2018
Paid in the year0.0040.0120.0090.0120.006

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.